CASP7

Across TCGA pan-cancer cohorts, CASP7 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CASP7 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CASP7 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CASP7 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, GBM, and HNSC are the cancer types where CASP7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.471	0.206	<.001	28	view →
GBM	DFS	Median	All	0.255	0.476	.002	9	view →
HNSC	OS	Median	III,IV	1.000	0.484	.038	4	view →
UCEC	DFS	Tertile	All	0.949	0.853	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CASP7–PDAC (DFS)

Open the PDAC breakdown →